



Biotech Daily

Thursday April 2, 2015

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: COMPUMEDICS UP 32%, UNIVERSAL BIO DOWN 6%**
- * **CYTOMATRIX RAISES \$6m**
- * **MEDIBIO RAISES \$2.6m, TAKES INVATEC, CHRIS INDERMAUR CHAIRMAN**
- * **IMMURON APPOINTS DR LEEARNE HINCH CEO**
- * **QRX PLEADS SCHULTZ TO ASX 100% QUERY**
- * **NOVOGEN HIRES NEW YORK'S PCG FOR US INVESTOR AWARENESS**

MARKET REPORT

The Australian stock market was up 0.64 percent on Thursday April 2, 2015 with the S&P ASX 200 up 37.8 points to 5,898.6 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 11 fell, 11 traded unchanged and one was untraded.

Compumedics was the best, up four cents or 32.0 percent to 16.5 cents with 398,384 shares traded, followed by Optiscan up 11.3 percent to 6.9 cents with 195,424 shares traded and Patrys up 10 percent to 1.1 cents with 630,000 shares traded.

Pharmaxis, Tissue Therapies and Viralytics climbed four percent or more; Anteo, Circadian and Prima were up more than three percent; Genetic Technologies, IDT and Osprey rose more than two percent; Living Cell, Medical Developments and Sirtex were up more than one percent; with Benitec, CSL, Nanosonics and Resmed up by less than one percent.

Universal Biosensors led the falls, down 1.5 cents or six percent to 23.5 cents with 266,999 shares traded.

Clinuvel lost 5.6 percent; Oncosil shed 4.8 percent; Acrux fell 3.45 percent; Admedus, Atcor and Mesoblast were down more than two percent; Antisense, Avita and Ellex were down more than one percent; with Cochlear and Impedimed down by less than one percent.

CYTOMATRIX

Cytomatrix says its “heavily oversubscribed” placement has raised \$6.2 million of a hoped-for \$2.5 million to \$3.5 million at 19 cents a share (BD: Nov 3, 2014; Feb 10, 2015).

Cytomatrix said there was “overwhelming interest shown by sophisticated private and institutional investors” with new shareholders in Australia, Singapore, UK, China and Hong Kong.

Cytomatrix executive chairman Ben Bergo said the capital “enables us to progress several pre-clinical activities and continue important business development as we look to complement our world leading expansion platform with new technologies”.

The company said that the funds would be used to continue research and development activities and corporate expansion, including the development of the final bioreactor design and acceleration of development projects with potential partners, the expansion of the Cytomatrix team, including a head of regulatory matters and quality control, a research manager and a clinical projects manager, the start of a phase I high dose chemotherapy trial and planning for a US phase IIb trial in bone marrow transplantation.

Cytomatrix is a public unlisted company.

MEDIBIO (FORMERLY BIOPROSPECT)

Medibio says it has raised \$2,607,000 at 30 cents a share and completed the acquisition of Invatec for its heart rate test for depression and other mental health disorders.

Medibio said that it would issue 25,537,500 shares to the vendor shareholders of Invatec and a further 19,890,000 shares could be issued for commercial milestone achievements over the next five years.

The company said that Chris Indermaur had been appointed as Medibio's chairman effective from the close of business today.

Medibio was unchanged at 29.5 cents.

IMMURON

Immuron says it has appointed Dr Leeorne Hinch as chief executive officer, effective immediately.

Immuron said that Dr Hinch was a biotechnology executive and consultant with more than 20 years experience in the lifescience industry, in general management, strategy, fundraising, technology commercialization, business development and marketing.

The company said that most recently, Dr Hinch was the director of Ingeneus Solutions providing advice and commercialization expertise to protect, fund, develop and commercialize technologies.

Immuron said that Dr Hinch previously held executive and management positions with OBJ where she was the chief operating officer, as well as Holista Colltech, Milne Agrigroup, Virbac Australia and Mars Petcare UK.

The company said that Dr Hinch held Bachelor of Science and Bachelor of Veterinary Medicine and Surgery degrees from Murdoch University and a Master of Business Administration from Curtin University.

Immuron said it thanked interim chief executive officer Amos Meltzer for his contribution to the development of Immuron during the last four and half years.

Immuron was untraded at 16 cents.

[QRX PHARMA](#)

QRX has told the ASX that it is not aware of any information it has not announced which, if known, could explain recent trading in its securities.

The ASX said the company's share price rose 100 percent from one cent on March 30 to two cents on April 2, 2015 and noted an increase in trading volume.

QRX was unchanged at 1.6 cents with one million shares traded.

[NOVOGEN](#)

Novogen says it has hired the New York-based public relations firm, PCG Advisory, for its investor-awareness program in the US.

Novogen was unchanged at 23 cents with 1.4 million shares traded.